Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jul-Aug;34(4):2173-2177.
doi: 10.21873/invivo.12026.

Hysterectomy for Recurrent/Residual Cervical Cancer Following Definitive Radiotherapy

Tadaharu Nakasone  1 , Yusuke Taira  2 , Yuko Shimoji  2 , Yoshihisa Arakaki  2 , Tomoko Nakamoto  2 , Takuma Ooyama  2 , Wataru Kudaka  2 , Itomi Kaneshima  2 , Kumiko Nishihira  2 , Keiko Mekaru  2 , Yoichi Aoki  2
Affiliations

Hysterectomy for Recurrent/Residual Cervical Cancer Following Definitive Radiotherapy

Tadaharu Nakasone et al. In Vivo. 2020 Jul-Aug.

Abstract

Background/aim: Radical hysterectomy has been used for local recurrent or persistent (LR) cervical cancer after radiotherapy (RT), but the rate of serious complications is high and tolerance is low. This study determined the efficacy, safety, and prognostic factors of adjuvant simple hysterectomy in LR cervical cancer post-RT.

Patients and methods: A total of 21 patients who underwent hysterectomy for LR cervical cancer post-RT in our Department between May 2007 and September 2018 were included in the study. Primary, definitive RT was performed. Histological response by definitive RT in the extirpated uterus was classified on the basis of histological response criteria: effect (Ef) 0-3.

Results: The 5-year overall survival (OS) and disease-free survival (DFS) rates were 51.9% and 50.1%, respectively. Ef 1 was significantly associated with poorer prognosis compared to Ef 2 or Ef 3.

Conclusion: Adjuvant hysterectomy could be a treatment of choice for LR cervical cancer post-RT.

Keywords: Cervical cancer; hysterectomy; radiotherapy.

PubMed Disclaimer

Conflict of interest statement

The Authors declare that there are no conflicts of interest regarding the publication of this paper.

Figures

Figure 1
Figure 1. Kaplan-Meier curves for OS and DFS in the study population (N=21). The 5-year OS and DFS rates were 51.9% and 50.1%, respectively. OS: Overall survival; DFS: disease-free survival.
Figure 2
Figure 2. Kaplan-Meier curves for OS and DFS according to histological response (Ef 1 vs. Ef 2 or Ef 3). The 5-year OS was 88.9% in Ef 2 or Ef 3 patients and 22.5% in Ef 1 patients. The 5-year DFS was 78.8% in Ef 2 or Ef 3 patients and 24.2% in Ef 1 patients.
See this image and copyright information in PMC

References

    1. Rose PG, Ali S, Watkins E, Thigpen JT, Deppe G, Clarke-Pearson DL, Insalaco S, Gynecologic Oncology Group Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25(19):2804–2810. doi: 10.1200/JCO.2006.09.4532. - DOI - PubMed
    1. Stehman FB, Ali S, Keys HM, Muderspach LI, Chafe WE, Gallup DG, Walker JL, Gersell D. Radiation therapy with or without weekly cisplatin for bulky stage 1B cervical carcinoma: follow-up of a Gynecologic Oncology Group trial. Am J Obstet Gynecol. 2007;197(5):503.e1–503.e6. doi: 10.1016/j.ajog.2007.08.003. - DOI - PMC - PubMed
    1. Toita T, Kato S, Ishikura S, Tsujino K, Kodaira T, Uno T, Hatano K, Sakurai H, Niibe Y, Kazumoto T, Nishimura T, Kitagawa R, Fukutani M, Oguchi M, Umayahara K, Hirashima Y, Aoki Y, Takizawa K, Disease Committee of Radiation Oncology, Japanese Gynecologic Oncology Group Radiotherapy quality assurance of the Japanese Gynecologic Oncology Group study (JGOG1066): a cooperative phase II study of concurrent chemoradiotherapy for uterine cervical cancer. Int J Clin Oncol. 2011;16(4):379–386. doi: 10.1007/s10147-011-0196-4. - DOI - PubMed
    1. Umayahara K, Takekuma M, Hirashima Y, Noda SE, Ohno T, Miyagi E, Hirahara F, Hirata E, Kondo E, Tabata T, Nagai Y, Aoki Y, Wakatsuki M, Takeuchi M, Toita T, Takeshima N, Takizawa K. Phase II study of concurrent chemoradiotherapy with weekly cisplatin and paclitaxel in patients with locally advanced uterine cervical cancer: The JACCRO GY-01 trial. Gynecol Oncol. 2016;140(2):253–258. doi: 10.1016/j.ygyno.2015.12.008. - DOI - PubMed
    1. Ebina Y, Mikami M, Nagase S, Tabata T, Kaneuchi M, Tashiro H, Mandai M, Enomoto T, Kobayashi Y, Katabuchi H, Yaegashi N, Udagawa Y, Aoki D. Japan Society of Gynecologic Oncology guidelines 2017 for the treatment of uterine cervical cancer. Int J Clin Oncol. 2019;24(1):1–19. doi: 10.1007/s10147-018-1351-y. - DOI - PubMed

MeSH terms